Table 3. Adjusted HRs of Late All-Cause, Relapse-Related, and Non–Relapse-Related Mortality Among 1388 Individuals Who Lived 2 Years or More After Allogeneic BMT in Childhood.

Variable	All-Cause Mortality		Relapse-Related Mortality		Non–Relapse-Related Mortality
	Adjusted HR (95% CI)	P Value	Adjusted HR (95% CI)	P Value	Adjusted HR (95% CI)	P Value
Sex
Male	0.93 (0.74-1.18)	.60	1.26 (0.74-2.25)	.40	0.94 (0.70-1.27)	.70
Female	1 [Reference]		1 [Reference]		1 [Reference]
Race/ethnicity
Non-Hispanic white	1 [Reference]		1 [Reference]		1 [Reference]
Non-Hispanic black	1.53 (0.91-2.57)	.10	0.75 (0.11-2.66)	.70	1.62 (0.81-3.01)	.10
Hispanic	0.86 (0.59-1.25)	.40	0.64 (0.23-1.48)	.30	1.00 (0.63-1.56)	.99
Other	1.24 (0.78-1.95)	.40	1.03 (0.31-2.62)	>.99	1.30 (0.71-2.21)	.40
Unknown	0.30 (0.04-2.17)	.20	NA	NA	0.51 (0.03-2.37)	.50
Age at BMT, ya	1.03 (1.01-1.05)	.004	1.03 (0.98-1.07)	.20	1.03 (1.00-1.06)	.03
Year of BMT
<1990	1 [Reference]		1 [Reference]		1 [Reference]
1990-1999	0.64 (0.47-0.89)	.008	0.74 (0.38-1.43)	.40	0.67 (0.44-1.01)	.06
2000-2010	0.49 (0.31-0.76)	.002	0.67 (0.28-1.51)	.30	0.46 (0.25-0.80)	.01
Type of donor
Related	1 [Reference]
Unrelated	1.06 (0.76-1.70)	.74	0.71 (0.34-1.43)	.40	1.30 (0.86-1.95)	.20
Source of stem cells
Bone marrow	1 [Reference]		1 [Reference]		1 [Reference]
Cord blood	0.83 (0.52-1.34)	.50	0.67 (0.22-1.82)	.40	0.96 (0.53-1.68)	.90
PBSC	1.77 (1.01-3.11)	.05	0.96 (0.24-3.14)	.90	2.39 (1.21-4.65)	.01
Primary diagnosis
ALL	1 [Reference]		1 [Reference]		1 [Reference]
AML or MDS	0.72 (0.53-0.99)	.04	0.39 (0.18-0.80)	.01	0.79 (0.53-1.16)	.20
Inborn errors of metabolism	0.98 (0.61-1.57)	.90	1.27 (0.49-3.28)	.60	0.84 (0.45-1.52)	.50
Severe aplastic anemia	0.33 (0.19-0.57)	<.001	0.09 (0.01-0.48)	.03	0.36 (0.17-0.71)	.004
Fanconi anemiab	0.49 (0.26-0.94)	.03	NA	NA	0.70 (0.32-1.43)	.40
Chronic myelogenous leukemia	0.53 (0.32-0.88)	.02	0.24 (0.04-0.85)	.06	0.60 (0.31-1.08)	.10
Other malignant diseasec	0.70 (0.39-1.25)	.20	0.87 (0.25-2.35)	.80	0.82 (0.39-1.58)	.60
Immune disorders	0.32 (0.14-0.74)	.006	0.24 (0.01-1.38)	.20	0.14 (0.02-0.48)	.009
Sickle cell disease or thalassemia	0.46 (0.13-1.56)	.20	0.74 (0.04-4.97)	.80	0.47 (0.07-1.72)	.30
Other nonmalignant diseased	1.03 (0.43-2.44)	>.99	0.71 (0.04-3.90)	.70	0.79 (0.19-2.26)	.70
Disease status at BMT
Standard risk of relapsee	1 [Reference]		1 [Reference]		1 [Reference]
High risk of relapse	1.95 (1.45-2.63)	<.001	1.57 (0.80-2.99)	.20	2.05 (1.41-2.94)	<.001
Conditioning regimen
Total body irradiation plus cyclophosphamide	1 [Reference]		1 [Reference]		1 [Reference]
Busulfan plus cyclophosphamide	0.62 (0.41-0.95)	.03	0.63 (0.27-1.47)	.30	0.71 (0.41-1.19)	.20
Others	0.88 (0.64-1.21)	.40	0.73 (0.36-1.44)	.30	0.93 (0.62-1.38)	.70

Abbreviation: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BMT, blood or marrow transplantation; MDS, myelodysplastic syndrome; HR, hazard ratio; NA, not applicable; PBSC, peripheral blood stem cells.

^aAge included in the model as a continuous variable.

^bIncludes Fanconi anemia, Diamond Blackfan anemia, and Shwachman-Diamond syndrome.

^cIncludes 27 with non-Hodgkin lymphoma, 7 with Hodgkin lymphoma, 8 with neuroblastoma, 2 with unspecified leukemia, and 20 with histiocytosis.

^dIncludes 1 with megakaryocytosis, 3 with dyskeratotis congenita, 8 with epidermolysis bullosa, 1 with Kostmann agranulocytosis, 11 with osteopetrosis, and 1 with paroxysmal nocturnal hemoglobinuria.

^eFirst or second complete remission after acute leukemia or lymphoma or first chronic phase of chronic myelogenous leukemia or severe aplastic anemia, all others high risk.